177 related articles for article (PubMed ID: 20739919)
1. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
Templeton I; Peng CC; Thummel KE; Davis C; Kunze KL; Isoherranen N
Clin Pharmacol Ther; 2010 Oct; 88(4):499-505. PubMed ID: 20739919
[TBL] [Abstract][Full Text] [Related]
2. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
3. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
Templeton IE; Thummel KE; Kharasch ED; Kunze KL; Hoffer C; Nelson WL; Isoherranen N
Clin Pharmacol Ther; 2008 Jan; 83(1):77-85. PubMed ID: 17495874
[TBL] [Abstract][Full Text] [Related]
4. Role of itraconazole metabolites in CYP3A4 inhibition.
Isoherranen N; Kunze KL; Allen KE; Nelson WL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1121-31. PubMed ID: 15242978
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
[TBL] [Abstract][Full Text] [Related]
6. In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation.
Vanhove T; Annaert P; Knops N; de Loor H; de Hoon J; Kuypers DRJ
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):50-55. PubMed ID: 29989304
[TBL] [Abstract][Full Text] [Related]
7. Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Kunze KL; Nelson WL; Kharasch ED; Thummel KE; Isoherranen N
Drug Metab Dispos; 2006 Apr; 34(4):583-90. PubMed ID: 16415110
[TBL] [Abstract][Full Text] [Related]
8. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
[TBL] [Abstract][Full Text] [Related]
11. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
12. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.
Peng CC; Shi W; Lutz JD; Kunze KL; Liu JO; Nelson WL; Isoherranen N
Drug Metab Dispos; 2012 Mar; 40(3):426-35. PubMed ID: 22106171
[TBL] [Abstract][Full Text] [Related]
13. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
14. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
[TBL] [Abstract][Full Text] [Related]
15. In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A.
Krasulova K; Dvorak Z; Anzenbacher P
Xenobiotica; 2019 Jan; 49(1):36-42. PubMed ID: 29320899
[TBL] [Abstract][Full Text] [Related]
16. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
Zhang X; Quinney SK; Gorski JC; Jones DR; Hall SD
Drug Metab Dispos; 2009 Aug; 37(8):1587-97. PubMed ID: 19420129
[TBL] [Abstract][Full Text] [Related]
17. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
[TBL] [Abstract][Full Text] [Related]
19. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]